ClinicalTrials.gg
TerminatedNCT02266147Updated Sep 4, 2020Results posted

Study of SD-101 in Combination With Localized Low-dose Radiation in Patients With Untreated Low-grade B-cell Lymphoma

A Phase 1/2 interventional study of SD-101 and Radiation therapy in B-cell Lymphoma, sponsored by Dynavax Technologies Corporation. Terminated at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-04.

Sponsored by Dynavax Technologies Corporation (part of Sanofi) · Phase 1/2, Interventional, and Treatment

Why this study was terminated
The sponsor terminated the trial early because there was sufficient data to make a decision about SD-101 in the lymphoma development program.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
29
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 398 studies in Lymphoma, B-Cell with a site in United States — 91 open to participants now, 157 under way, 12 of them phase 3. Lymphoma, B-Cell · United States.

Enrollment
225th of 380
29 · median 37
Started
2014
with 9 others
Phase 1/2
75 of 398
20 open now
Registered
125th of 398
by date

Among the 398 studies in Lymphoma, B-Cell with a site in United States, this one is the 225th largest by enrollment of the 380 interventional ones that give a count, is one of 10 that started in 2014, is one of 75 in phase 1/2, and was the 125th registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

91 of the 398 studies in Lymphoma, B-Cell with a site in United States are open now. Recruiting first, the newest first:

86 more — sign in →

All 91 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 398 studies in Lymphoma, B-Cell with a site in United States, or all of them as a file.
02

Study summary

To assess the safety and tolerability of escalating doses of SD-101 in combination with localized low-dose radiation therapy in adult subjects with untreated low-grade B-cell lymphoma.

03

Conditions studied

  • B-cell Lymphoma

Browse trials for

Keywords

  • Low Grade B-cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed, untreated, low-grade B-cell lymphoma, including follicular (Grade 1, 2, or 3A) [Harris, Swerdlow et al. 2008] or marginal, or CLL/SLL with lymph node involvement.
  • At least 2 sites of per Cheson criteria (must measure at least 1.5 cm in any diameter or 1.0 cm in the shortest diameter if one of the diameters is not ≥ 1.5 cm), one of which must be palpable and easily accessible in a low-risk site (eg, inguinal, axillary, cervical, subcutaneous) for intratumoral injection (denoted as "Lesion A" in Treatment Cycle 1) and at least one additional untreated lesion that is located outside the radiation field of the treated lesion (Lesion A) and is accessible for an FNA aspirate.
  • (ECOG) Performance Status (PS) of 0 or 1
  • Aged 18 years and older
  • (ANC) ≥ 1500/mm3
  • count > 100,000/µL
  • Serum creatinine (Cr) ≤ 1.5 x (ULN).
  • Serum total ≤ 1.5 x the ULN.
  • (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN
  • or prothrombin time (PT) ≤ 1.5 x ULN unless subject is receiving anticoagulant therapy and the PT or partial thromboplastin time (PTT) must be within the therapeutic range of the intended use of anticoagulants.
  • Activated PTT (aPTT) ≤ 1.5 x ULN unless subject is receiving anticoagulant therapy, and the PT or PTT is within therapeutic range of intended use of anticoagulants.
  • Female subjects must have a negative urine or serum pregnancy test within 72 hours prior to taking study medication if of as defined in this protocol. Women of childbearing potential (WOCBP) must be willing to use 2 medically acceptable method of from Day 1 through 120 days after the last dose of trial treatment. The 2 medically acceptable birth control methods can be either 2 barrier methods or a barrier method plus a hormonal method to prevent pregnancy. The following are considered adequate barrier methods of contraception: diaphragm, condom (by the partner), cooper intrauterine device, sponge, or spermicide as per local regulations or guidelines. Appropriate hormonal contraceptives will include any registered and marketed contraceptive agent that contains an estrogen and/or a progestational agent (including oral, subcutaneous, intrauterine, or intramuscular agents).
  • Ability to understand and sign form (ICF) and comply with treatment protocol

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of immunodeficiency or is receiving systemic therapy or any other form of therapy (including immune modulators or systemic corticosteroids) within 7 days prior to study enrollment.
  • Positive for (HBsAg reactive), ribonucleic acid (RNA) qualitative, or (HIV)( HIV 1/2 antibodies)
  • Diagnosis of mantle or diffuse large-cell lymphoma, Grade 3B follicular lymphoma [Harris, Swerdlow et al. 2008] or gastric mucosa-associated lymphoid tissue (MALT) lymphoma
  • pleural effusion
  • Active infection including cytomegalovirus
  • Pregnant or breast feeding within the projected duration of trial participation through 4 months after the last dose of study treatment.
  • disease including systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, Sjӧgren's syndrome, autoimmune thrombocytopenia, history of uveitis, or other if clinically significant
  • Lymphoma involvement of the central nervous system
  • Received any prior therapy for lymphoma
  • Use of any agent within the last 28 days
  • Serious, non-healing wound, ulcer, or bone fracture.
  • If a subject received major surgery, must have recovered adequately from the toxicity and/or complications from the intervention prior to enrollment.
  • Clinically significant cardiovascular disease (eg, uncontrolled hypertension, myocardial infarction, unstable angina), (NYHA) Grade II or greater congestive heart failure, serious cardiac arrhythmia requiring medication within 1 year prior to Day -1 (Visit 1); Grade II or greater peripheral vascular disease at study entry
  • Any other significant medical or psychiatric condition, laboratory abnormality, or difficulty complying with protocol requirements that may increase the risk associated with study participation or study drug administration that may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for this study
  • History of sensitivity to any component of SD-101
  • A diagnosis of cancer within the last 3 years prior to enrollment or any known additional that is progressing or requires active treatment. Exceptions are B-cell lymphoma, basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, and in situ cervical cancer.
  • Is taking systemic corticosteroids (more than 3 consecutive days) or other immunomodulators or immune suppressive medication
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    SD-101 in combination with low-dose radiation

    PART 1 * Radiation: 2 fractions of 2 Gy over 2 days at Days -1 and 1 * COHORT 1: 1 mg/mL at Days 1, 8, 15, 22, and 29 * COHORT 2: 2 mg/mL at Days 1, 8, 15, 22, and 29 * COHORT 3: 4 mg/mL at Days 1, 8, 15, 22, and 29 * COHORT 4: 8 mg/mL at Days 1, 8, 15, 22, and 29 PART 2 Cycle 1: Required * Radiation: 2 fractions of 2 Gy over 2 days at Days -1 and 1 * COHORT 1: 1 mg/mL at Days 1, 8, 15, 22, and 29 * COHORT 2: 8 mg/mL at Days 1, 8, 15, 22, and 29 Cycle 2: Optional * Radiation: 2 fractions of 2 Gy over 2 days at Days 180 and 181 * COHORT 1: 1 mg/mL at Days 181, 188, 195, 202, and 209 * COHORT 2: 8 mg/mL at Days 181, 188, 195, 202, and 209

    Drug: SD-101 · Radiation: Radiation therapy

Interventions

  • DrugSD-101
  • RadiationRadiation therapy
06

What researchers measure

Primary outcomes

  1. Number of Participants Experiencing Dose-limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD).

    Time frame: Up to Day 36

  2. Number of Participants Experiencing Injection-site Reactions (ISRs)

    Injection site reaction 1 = Redness, Injection site reaction 2 = Swelling, Injection site reaction 3 = Pain

    Time frame: Up to Day 36

  3. Number of Participants Experiencing Serious Adverse Events (SAEs)

    Time frame: Up to 38 weeks

  4. Pharmacodynamic Profile - Expression of IFN-responsive Genes (GBP-1, ISG-54, MCP-1, and MxB)

    Fold change of IFN-responsive gene expression relative to Day 8

    Time frame: Change from Day 8 to Day 9

Secondary outcomes

  1. Number of Participants With Preliminary Response - Local (Injected Lesions)

    Subjects with maximum decrease of 50% or greater in sum of products of diameters of lesions.

    Time frame: Up to 38 weeks

  2. Number of Participants With Preliminary Response - Systemic (Non-injected Lesions)

    Subjects with maximum decrease of 50% or greater in sum of products of diameters of lesions.

    Time frame: Up to 38 weeks

07

Results

Posted Sep 4, 2020
Limitations and caveats
The sponsor terminated the trial early because there was sufficient data to make a decision about SD-101 in the lymphoma development program.

Participant flow

PART 1: Dose Escalation
Participant flow — PART 1: Dose Escalation
Milestone1 mg/mL2 mg/mL4 mg/mL8 mg/mL
Started3334
Completed2000
Not completed1334
Withdrew: Physician decision0010
Withdrew: Lack of efficacy0211
Withdrew: Study terminated by sponsor0013
Withdrew: Other1100
PART 2: Dose Expansion
Participant flow — PART 2: Dose Expansion
Milestone1 mg/mL2 mg/mL4 mg/mL8 mg/mL
Started7009
Completed0000
Not completed7009
Withdrew: Lack of efficacy1001
Withdrew: Study terminated by sponsor6008

Outcome measures

PrimaryNumber of Participants Experiencing Dose-limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD).
Time frame:
Up to Day 36
Reported as:
Number · participants
Number of Participants Experiencing Dose-limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD).
participants1 mg/mL2 mg/mL4 mg/mL8 mg/mL
Number of Participants Experiencing Dose-limiting Toxicities (DLTs) and Maximum Tolerated Dose (MTD).0000
Statistical analysis
  • 1 mg/mL vs 2 mg/mL vs 4 mg/mL vs 8 mg/mL ·
PrimaryNumber of Participants Experiencing Injection-site Reactions (ISRs)

Injection site reaction 1 = Redness, Injection site reaction 2 = Swelling, Injection site reaction 3 = Pain

Time frame:
Up to Day 36
Reported as:
Count of participants · Participants
Number of Participants Experiencing Injection-site Reactions (ISRs)
Participants1 mg/mL2 mg/mL4 mg/mL8 mg/mL
Injection site reaction 14015
Injection site reaction 24122
Injection site reaction 37316
PrimaryNumber of Participants Experiencing Serious Adverse Events (SAEs)
Time frame:
Up to 38 weeks
Reported as:
Number · participants
Number of Participants Experiencing Serious Adverse Events (SAEs)
participants1 mg/mL2 mg/mL4 mg/mL8 mg/mL
Renal and urinary disorders0001
Respiratory, thoracic and mediastinal disorders0010
Total # of participants with SAEs0011
PrimaryPharmacodynamic Profile - Expression of IFN-responsive Genes (GBP-1, ISG-54, MCP-1, and MxB)

Fold change of IFN-responsive gene expression relative to Day 8

Time frame:
Change from Day 8 to Day 9
Reported as:
Geometric mean · Fold Change
Pharmacodynamic Profile - Expression of IFN-responsive Genes (GBP-1, ISG-54, MCP-1, and MxB)
Fold Change1 mg/mL2 mg/mL4 mg/mL8 mg/mL
Pharmacodynamic Profile - Expression of IFN-responsive Genes (GBP-1, ISG-54, MCP-1, and MxB)7.42 ± 4.788.06 ± 2.059.89 ± .597.78 ± 7.54
SecondaryNumber of Participants With Preliminary Response - Local (Injected Lesions)

Subjects with maximum decrease of 50% or greater in sum of products of diameters of lesions.

Time frame:
Up to 38 weeks
Reported as:
Count of participants · Participants
Number of Participants With Preliminary Response - Local (Injected Lesions)
Participants1 mg/mL2 mg/mL4 mg/mL8 mg/mL
Number of Participants With Preliminary Response - Local (Injected Lesions)6318
SecondaryNumber of Participants With Preliminary Response - Systemic (Non-injected Lesions)

Subjects with maximum decrease of 50% or greater in sum of products of diameters of lesions.

Time frame:
Up to 38 weeks
Reported as:
Count of participants · Participants
Number of Participants With Preliminary Response - Systemic (Non-injected Lesions)
Participants1 mg/mL2 mg/mL4 mg/mL8 mg/mL
Number of Participants With Preliminary Response - Systemic (Non-injected Lesions)2002

Adverse events

Collected over Up to 38 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1 mg/mL0/10 (0%)0/10 (0%)10/10 (100%)
2 mg/mL0/3 (0%)0/3 (0%)3/3 (100%)
4 mg/mL0/3 (0%)1/3 (33.3%)3/3 (100%)
8 mg/mL0/13 (0%)1/13 (7.7%)13/13 (100%)
Most frequent serious events
Most frequent serious events
Event1 mg/mL2 mg/mL4 mg/mL8 mg/mL
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/100/31/30/13
Focal segmental glomerulosclerosisRenal and urinary disorders0/100/30/31/13
Most frequent other events
Showing 10 of 120
Most frequent other events
Event1 mg/mL2 mg/mL4 mg/mL8 mg/mL
ChillsGeneral disorders8/102/33/313/13
FatigueGeneral disorders8/103/33/312/13
MalaiseGeneral disorders9/102/33/313/13
MyalgiaMusculoskeletal and connective tissue disorders7/103/33/313/13
HeadacheNervous system disorders8/103/33/311/13
PyrexiaGeneral disorders4/101/32/312/13
NasopharyngitisInfections and infestations1/102/30/31/13
NauseaGastrointestinal disorders2/101/30/38/13
Injection Site ErythemaGeneral disorders4/100/31/33/13
VomitingGastrointestinal disorders0/101/30/35/13

Baseline characteristics

Intent-to-treat population

Age, Categorical
Age, Categorical(Participants)1 mg/mL2 mg/mL4 mg/mL8 mg/mLTotal
<=18 years00000
Between 18 and 65 years722718
>=65 years311611
Age, Continuous
Age, Continuous(years)1 mg/mL2 mg/mL4 mg/mL8 mg/mLTotal
Mean56.9 ± 13.5356 ± 9.5461 ± 16.5262.7 ± 12.3259.8 ± 12.59
Sex: Female, Male
Sex: Female, Male(Participants)1 mg/mL2 mg/mL4 mg/mL8 mg/mLTotal
Female421613
Male612716
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)1 mg/mL2 mg/mL4 mg/mL8 mg/mLTotal
Hispanic or Latino00000
Not Hispanic or Latino10331329
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)1 mg/mL2 mg/mL4 mg/mL8 mg/mLTotal
American Indian or Alaska Native00000
Asian10001
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White8331226
More than one race00000
Unknown or Not Reported10012
Region of Enrollment
Region of Enrollment(Participants)1 mg/mL2 mg/mL4 mg/mL8 mg/mLTotal
United States10331329
08

Study locations

5 sites
  • Stanford University School of Medicine
    Stanford, California 94305-5151, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
09

References and documents

Publications

  • Mooney KL, Czerwinski DK, Shree T, Frank MJ, Haebe S, Martin BA, Testa S, Levy R, Long SR. Serial FNA allows direct sampling of malignant and infiltrating immune cells in patients with B-cell lymphoma receiving immunotherapy. Cancer Cytopathol. 2022 Mar;130(3):231-237. doi: 10.1002/cncy.22531. Epub 2021 Nov 15. PubMed 34780125 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Apr 2017 and a completion of Apr 2017. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2020, 3 years 5 months after primary completion. A results delay was requested in Mar 2020.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2014
First posted
Oct 16, 2014
Start
Oct 2014
Primary completionActual
Apr 2017
CompletionActual
Apr 2017
Results delay requested
Mar 6, 2020
Results first posted
Sep 4, 2020
Last update
Sep 4, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 4, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02266147
Responsible party
Sponsor
First posted
Oct 16, 2014
Start date
Oct 2014
Primary completion
Apr 2017
Completion
Apr 2017
Results posted
Sep 4, 2020
Last update
Sep 4, 2020

Study contacts

Abraham Leung, MD
study director · Dynavax Technologies Corporation

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nelitolimod

Start the discussion